Edmonton protocol

Jump to navigation Jump to search

WikiDoc Resources for Edmonton protocol

Articles

Most recent articles on Edmonton protocol

Most cited articles on Edmonton protocol

Review articles on Edmonton protocol

Articles on Edmonton protocol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Edmonton protocol

Images of Edmonton protocol

Photos of Edmonton protocol

Podcasts & MP3s on Edmonton protocol

Videos on Edmonton protocol

Evidence Based Medicine

Cochrane Collaboration on Edmonton protocol

Bandolier on Edmonton protocol

TRIP on Edmonton protocol

Clinical Trials

Ongoing Trials on Edmonton protocol at Clinical Trials.gov

Trial results on Edmonton protocol

Clinical Trials on Edmonton protocol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Edmonton protocol

NICE Guidance on Edmonton protocol

NHS PRODIGY Guidance

FDA on Edmonton protocol

CDC on Edmonton protocol

Books

Books on Edmonton protocol

News

Edmonton protocol in the news

Be alerted to news on Edmonton protocol

News trends on Edmonton protocol

Commentary

Blogs on Edmonton protocol

Definitions

Definitions of Edmonton protocol

Patient Resources / Community

Patient resources on Edmonton protocol

Discussion groups on Edmonton protocol

Patient Handouts on Edmonton protocol

Directions to Hospitals Treating Edmonton protocol

Risk calculators and risk factors for Edmonton protocol

Healthcare Provider Resources

Symptoms of Edmonton protocol

Causes & Risk Factors for Edmonton protocol

Diagnostic studies for Edmonton protocol

Treatment of Edmonton protocol

Continuing Medical Education (CME)

CME Programs on Edmonton protocol

International

Edmonton protocol en Espanol

Edmonton protocol en Francais

Business

Edmonton protocol in the Marketplace

Patents on Edmonton protocol

Experimental / Informatics

List of terms related to Edmonton protocol


The Edmonton Protocol is a method of implantation of pancreatic islets for the treatment of type 1 diabetes mellitus, specifically "brittle" type 1 diabetics prone to hypoglycemic unawareness. The protocol is named for the islet transplantation group at the University of Alberta in the Canadian city of Edmonton, where the protocol was first devised in the late 1990s.

Procedure

The Edmonton Protocol involves isolating islets from a cadaveric donor pancreas using a mixture of enzymes called Liberase™ (Roche). Each recipient receives islets from one to as many as three donors. The islets are infused into the patient's portal vein, and are then kept from being destroyed by the recipient's immune system through the use of two immunosuppressants, sirolimus and tacrolimus as well as a monoclonal antibody drug used in transplant patients called daclizumab.

History

Islet isolation and transplantation was pioneered by Paul Lacy throughout the 1960s. He and Walter Ballinger together were able to restore normoglycaemia in diabetic rats following the transplantation of isolated islets into the rodent's livers. Scientists have not yet successfully translated Dr. Lacy's success in rodents to humans.

The Edmonton Protocol was primarily developed by Dr James Shapiro (transplant surgeon), Jonathan Lakey Ph.D., Dr Edmond Ryan (endocrinologist), Gregory Korbutt Ph.D., Dr. Ellen Toth, Dr. Garth Warnock, Dr. Norman Kneteman, and Ray Rajotte Ph.D., at the University of Alberta Hospital and the Surgical-Medical Research Institute. The first patient was treated using the Edmonton Protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000.

The NEJM report was exciting for the diabetes field because all seven patients undergoing the Edmonton Protocol remained insulin-independent after an average of 12 months.

Current review

It has recently been reported that of thirty-six patients transplanted, only sixteen (44%) were insulin-independent after one year; ten (28%) had partial graft function after one year; and ten (28%) had complete graft loss after one year. Insulin independence is not usually sustainable in the long term, but the transplanted islets still function enough to provide protection from severe hypoglycemic episodes and unawareness.

The major problem limiting islet transplantation therapy for type 1 diabetic individuals is the lack of organ donors.

References

  • [1] Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
  • [2] Saffitz JE, Schmidt RE, McDaniel ML. Dr. Paul Eston Lacy, 1924–2005. American Journal of Pathology. 2005;167:299-300.
  • [3] Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9.
  • [4] Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg. 2001 Apr;25(4):487-96.
  • [5] Shapiro AMJ, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318-1330.
  • [6] O'Gorman D, Kin T, Murdoch T, Richer B, McGhee-Wilson D, Ryan EA, Shapiro AMJ, Lakey JRT. The standardization of pancreatic donors for islet isolations. Transplantation. 2005 Sep;80(6):801-806.

External links

Template:Organ transplantation

[7]

Template:WH Template:WikiDoc Sources Template:Jb1